FOXC2 and cancer: In univariate survival analyses of Gleason score 7 patients, strong FOXC2 expression was significantly associated with clinical recurrence (p = 0.047), skeletal metastasis (p = 0.011) and cancer‐specific survival (p = 0.006) (Figure 2 and Table 2).